Oruka Therapeutics director granted 9,136 stock options

Oruka Therapeutics director Carl Dambkowski received a grant of 9,136 stock options on Common Stock.

Rhea-AI Filing Summary

Oruka Therapeutics director Carl Dambkowski received a grant of 9,136 stock options on Common Stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The grant was a compensation-related award, bringing his directly held stock options to 9,136. According to the vesting terms, the option vests as to 1/12 of the underlying shares monthly beginning on June 2, 2026, so the award becomes exercisable gradually over time rather than immediately.

Insights

Equity compensation analyst

Routine director option grant with time-based monthly vesting.

Director Carl Dambkowski received 9,136 stock options for Oruka Therapeutics, Inc. as a grant or award, with an exercise price of $55.23 and expiration on June 1, 2036. This is a derivative acquisition, not an open-market purchase.

The award vests in equal monthly installments, 1/12 of the underlying 9,136 shares each month starting on June 2, 2026. Such time-based vesting aligns director incentives with longer-term company performance but does not, by itself, signal a change in outlook.

No other derivative positions are listed in this snapshot, and there are no same-day sales or tax-withholding dispositions. As disclosed, this looks like standard equity compensation, with its impact depending mainly on future stock performance and ongoing vesting.

Insider Trade Summary

Grant/Award: 9,136 shares

Grant/Award 1 txn

Insider Dambkowski Carl

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	9,136	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 9,136 contracts (Direct)

Footnotes (1)

1. F1. The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

Key Figures

Options granted: 9,136 options Exercise price: $55.23 per share Expiration date: June 1, 2036 +3 more

6 metrics

Options granted 9,136 options Grant of stock options reported on June 2, 2026

Exercise price $55.23 per share Exercise price for the 9,136 stock options

Expiration date June 1, 2036 Option expiry for granted stock options

Underlying shares 9,136 shares Common Stock underlying the option grant

Post-transaction options held 9,136 options Total stock options held directly after the grant

Vesting schedule 1/12 monthly from June 2, 2026 Time-based vesting of underlying shares

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vests as to 1/12, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "55.2300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests as to 1/12 financial

"The option vests as to 1/12 of the underlying shares monthly"

expiration date financial

"expiration_date: "2036-06-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Oruka Therapeutics (ORKA) director Carl Dambkowski report in this Form 4?

He reported receiving a grant of 9,136 stock options on Oruka Therapeutics Common Stock. The options are a compensation-related award, not an open-market purchase, and increase his directly held stock option position to 9,136 derivatives following the transaction.

What are the key terms of Carl Dambkowski’s 9,136 Oruka Therapeutics stock options?

The 9,136 stock options have an exercise price of $55.23 per share and expire on June 1, 2036. They relate to Oruka Therapeutics Common Stock and were acquired as a grant or award rather than through buying shares in the open market.

How do the Oruka Therapeutics options granted to Carl Dambkowski vest over time?

The option vests in 12 equal monthly installments beginning June 2, 2026. Specifically, 1/12 of the 9,136 underlying Common Stock shares vests each month, so the award becomes exercisable gradually rather than immediately after the grant date.

Did Carl Dambkowski buy or sell Oruka Therapeutics shares in the market?

No market buy or sell occurred in this Form 4. The filing shows a grant or award acquisition of 9,136 stock options, coded as an “A” transaction, which represents equity compensation rather than an open-market trade of Oruka Therapeutics Common Stock.

How many Oruka Therapeutics stock options does Carl Dambkowski hold after this grant?

After the reported transaction, he holds 9,136 stock options directly. This total matches the size of the grant, indicating the reported award established or increased his derivative position to 9,136 options linked to Oruka Therapeutics Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:52 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$55.23	06/02/2026		A		9,136		(1)	06/01/2036	Common Stock	9,136	$0	9,136	D

Explanation of Responses:

1. The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

	/s/ Paul Quinlan, as attorney-in-fact for Carl Dambkowski	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)